Search

Your search keyword '"Clinical Research Unit"' showing total 12,075 results
Start Over Author "Clinical Research Unit"
12,075 results on '"Clinical Research Unit"'

1. FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME)

Author

Universidad Peruana Cayetano Heredia- subcontractor to UCSF as local Sponsor, PATH, Stanford University, Eijkman Oxford Clinical Research Unit, Indonesia, Menzies School of Health Research, and National Institute of Allergy and Infectious Diseases (NIAID)

Published
2024

4. Rural South and Southeast Asia Household Health Survey (SEACTN-HHS)

Author

Mahidol Oxford Tropical Medicine Research Unit, Chiang Rai Clinical Research Unit, Thailand, Myanmar Oxford Clinical Research Unit, Yangon, Myanmar, Bangladesh Rural Advancement Committee, Dhaka, Bangladesh, and Cambodia Action for Health Development (AHEAD)

Published
2024

7. R21/Matrix-M in African Children Against Clinical Malaria

Author

Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso, Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest, Malaria Research and Training Center, Bamako, Mali, KEMRI-Wellcome Trust Collaborative Research Program, Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania, and London School of Hygiene and Tropical Medicine

Published
2024

19. Dual therapy based on co-formulated darunavir/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial

Author

Cahn, Pedro, Cecchini, Diego, Pryluka, Daniel, Sánchez, Marisa, Lopardo, Gustavo, Altclas, Javier, Rolón, María José, Multicentric studies unit(UEM), Clinical research Unit (CRS), Figueroa, M.I., Sued, O., Cecchini, D., Sanchez, M., Rolón, M.J., Lopardo, G., Ceschel, M., Mernies, G., De Stefano, M., Patterson, P., Gun, A., Fink, V., Ortiz, Z., and Cahn, P.

Published
2024
Full Text
View/download PDF

20. Serological Screen and Treat Trial for Plasmodium Vivax (SSAT)

Author

Eijkman Institute for Molecular Biology, Eijkman Oxford Clinical Research Unit, Indonesia, Walter and Eliza Hall Institute of Medical Research, Rumah Sakit Umum Daerah Mimika, Universitas Sumatera Utara, and Inge Sutanto, Professor

Published
2023

21. Prevalence Survey of Antimalarial Drug Resistance Markers

Author

Mahidol University, Worldwide Antimalarial Resistance Network, Mahidol Oxford Tropical Medicine Research Unit, Myanmar Oxford Clinical Research Unit, Shoklo Malaria Research Unit, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Oxford University Clinical Research Unit, Vietnam, and Cambodia Oxford Medical Research Unit

Published
2022

23. Targeted Chemo-elimination (TCE) of Malaria (TME)

Author

Mahidol Oxford Tropical Medicine Research Unit, National Centre for Parasitology, Entomology and Malaria Control, Cambodia, FHI 360, Oxford University Clinical Research Unit, Vietnam, National Malaria Control Program, Vietnam, Myanmar Oxford Clinical Research Unit, National Malaria Control Program, Myanmar, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, and Shoklo Malaria Research Unit

Published
2020

24. T-regulatory Cells in ALS (Tregs in ALS)

Author

Massachusetts General Hospital, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston, North East Amyotrophic Lateral Sclerosis Consortium, and Jason R. Thonhoff, Principal Investigator, Houston Methodist Neurological Institute

Published
2021

25. A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19 (B-EPIC)

Author

Fraser Health Authrority Department of Evaluation and Research Services, Surrey Memorial Hospital Clinical Research Unit, Centre for Health Evaluation and Outcome Sciences, Surrey Hospital Foundation, BC Support Unit, University of British Columbia, Ministry of Health, British Columbia, Clinical Trials BC (part of the BC Academic Health Science Network), and Gregory Haljan, MD, Principal Investigator

Published
2021

27. A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys

Author

Hügel, J, Schneider, J, Tran Ortega, D, Jentsch, EM, Rheinländer, S, Beyer, N, Estiri, H, Ammer-Herrmenau, C, Hessmann, E, König, AO, Ellenrieder, V, Sax, U, Clinical Research Unit 5002 (CRU 5002), Hügel, J, Schneider, J, Tran Ortega, D, Jentsch, EM, Rheinländer, S, Beyer, N, Estiri, H, Ammer-Herrmenau, C, Hessmann, E, König, AO, Ellenrieder, V, Sax, U, and Clinical Research Unit 5002 (CRU 5002)

Published
2024

33. Genetic Autopsy and Sudden Death (AGEMOS)

Author

Pathology department and forensic Institute, Raymond Poincaré hospital, Garches, Referal Center for Inherited cardiac diseases, Pitié Salpêtrière Hospital, Paris, Pitié-Salpêtrière Hospital, Clinical research Unit, Ambroise Paré Hospital, Boulogne Billancourt, Cardiogenetic and molecular and cellular myogenetic functionnal unit Pitié Salpêtrière hospital, Paris, and Molecular and medical Virology Laboratory, Medical School, Reims

Published
2017

38. Novel Treatment for Coronary Artery Disease

Author

Clinical Research Unit at the Instituto Docente de Urologia, Northern Metropolitan Hospital, Venezuelan Foundation of Heart Failure, and Antonio Delgado Leon, MD, Prof. of Medicine, MD

Published
2013

39. Treatment of Coronary Heart Disease With Amiloride

Author

Clinical Research Unit at the Docent Institute of Urology, Northern Metropolitan Hospital, Venezuelan Foundation of Heart Failure, and Antonio Delgado Leon, MD, Prof. of Medicine, MD

Published
2012

43. Newer Long-Acting Basal Insulin Preparations

Author

Lawrence Blonde and Ochsner Diabetes Clinical Research Unit

Subjects
medicine.medical_specialty, Endocrinology, Long acting, business.industry, Endocrinology, Diabetes and Metabolism, Internal medicine, Basal insulin, medicine, business
Published
2017
Full Text
View/download PDF

45. Comparison of phenol red and polyethyleneglycol as nonabsorbable markers for the study of intestinal absorption in humans

Author

From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich, From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich; Royal East Sussex Hospital, Sussex, England, From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich; Medical Research Council, Department of Gastroenterology, Central Middlesex Hospital, London, England, Ann Arbor, French, Arthur B., Brown, Isabel F., Good, Christopher J., McLeod, Graham M., From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich, From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich; Royal East Sussex Hospital, Sussex, England, From the Department of Internal Medicine, Gastroenterology Section, University of Michigan Medical School, Ann Arbor, Mich; Clinical Research Unit, W4644 University of Michigan Hospital, 48104, Ann Arbor, Mich; Medical Research Council, Department of Gastroenterology, Central Middlesex Hospital, London, England, Ann Arbor, French, Arthur B., Brown, Isabel F., Good, Christopher J., and McLeod, Graham M.

Abstract

When phenol red and polyethyleneglycol were used simultaneously as nonabsorbable markers in perfusion studies of the absorptive capacity of high jejunum in humans, apparent absorption was the same when calculated from either marker. This similar indication of dilution and of absorption by the two markers was found in normal subjects and in patients with nontropical sprue, whether aqueous or saline solutions of dextrose were infused. The similarity strengthens the evidence that either phenol red or polyethyleneglycol is a satisfactory???nonabsorbable??? marker compound to indicate dilution in perfusion studies of dextrose and electrolyte absorption in limited segments of human intestine.

Published
2006

46. Individual Trajectories in Asthma and COPD: A Longitudinal Perspective to Obstructive Lung Disease

Author

Helsingin yliopisto, lääketieteellinen tiedekunta, Hjelt-instituutti, Helsingfors universitet, medicinska fakulteten, Hjelt-institutet, University of Helsinki, Faculty of Medicine, Hjelt Institute, Department of Public Health, Faculty of Medicine, Clinical Research Unit for Pulmonary Diseases and Division of Pulmonology, Helsinki University Central Hospital, Helsinki, Finland, Koskela, Jukka, Helsingin yliopisto, lääketieteellinen tiedekunta, Hjelt-instituutti, Helsingfors universitet, medicinska fakulteten, Hjelt-institutet, University of Helsinki, Faculty of Medicine, Hjelt Institute, Department of Public Health, Faculty of Medicine, Clinical Research Unit for Pulmonary Diseases and Division of Pulmonology, Helsinki University Central Hospital, Helsinki, Finland, and Koskela, Jukka

Abstract

Managing chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) forms a notable burden on the healthcare system while the burden on an individual is equally notable as patients might suffer from a symptomatic disease for decades. However, not all asthma and COPD patients develop a disabling disease with frequent disease exacerbations and highest cost (in Quality Adjusted Life Years lost or healthcare spending). This variation in disease trajectories enables the analytical identification of distinct phenotypes over time. Retrospective data collected from a large number of patients could be used efficiently as the electronic health records are increasingly made available to researchers around the world. The aim of this project is to develop disease models based on longitudinal data to better capture the essential characteristics of obstructive lung disease, mainly focusing on COPD. Projects I III in this thesis are based on 2398 asthma and COPD patients retrospectively followed through electronic health records from year 2000 onwards. We aimed to analyse this real-world hospital based data using Hierarchical Models to assess the variation of development between individual patients over time. Unpublished Project IV is based on Health 2000 to 2011 follow-up study consisting of 1113 subjects from random Finnish population. The aim was to estimate Single Nucleotide Polymorphism (SNP) based heritability of Forced Expiratory Volume in 1 s (FEV1) level and development and to perform a Genome-Wide Association Study (GWAS) to identify possible genetic markers associated with FEV1 development over time. Our results suggest that the major determinants of Health Related Quality of Life (HRQoL) in mild or moderate COPD are the common comorbidities associated with COPD while in severe diseases the accentuated lung function has a major role. Over time, observable individual trajectories of HRQoL are presented in Asthma and COPD. Significant de, Krooniset ahtauttavat keuhkosairaudet, kuten keuhkoahtaumatauti (COPD) ja astma ovat merkittäviä kansansairauksia Suomessa. Jopa lähes kymmenys maan aikuisväestöstä kärsii astmasta, COPD:n esiintyvyys ikääntyneillä miehillä saattaa olla vielä tätäkin suurempi. Kroonisina tiloina ahtauttavat keuhkosairaudet aiheuttavat huomattavan taakan niitä sairastaville potilaille sekä suuria kustannuksia yhteiskunnalle. Merkittävä riskitekijä vaikealle keuhkosairaudelle on tupakointi, joka on tunnettu riskitekijä myös monelle muulle krooniselle sairaudelle. Kuitenkin vain osa tupakoivista ahtauttavaa keuhkosairautta sairastavista omaa voimakkaasti etenevän sairauden, joka pahimmillaan johtaa toistuviin intensiivistä hoitoa vaativiin sairauden pahenemisvaiheisiin ja ennenaikaiseen kuolemaan. Nykyisellään suuri osa resursseista kulutetaan intensiivisessä hoidossa, eikä niiden ennaltaehkäisyssä. On mahdollista, että etenevän ja huomattavia kustannuksia aiheuttavan keuhkosairauden taustalla on sille ominaisia perinnöllisiä tai ympäristöllisiä riskitekijöitä. Nämä riskitekijät ovat kuitenkin nykyisellään huonosti tunnettuja. Keuhkosairaus aiheuttaa oireita vasta keuhkojen toiminnan heikennyttyä jo merkittävästi, jonka jälkeen potilaan toimintakyky heikkenee nopeasti, mikäli sairaus edelleen etenee. Mikäli huonosti kehittyvät potilaat kyettäisiin paremmin tunnistamaan aikaisessa vaiheessa, olisi mahdollista kohdistaa hoito ja interventiot niitä eniten tarvitsevaan ryhmään. Tässä työssä on tutkittu erityisesti COPD:tä ja astmaa sairastavien potilaiden terveyteen liittyvän elämänlaadun ja keuhkojen toiminnan kehitystä yli ajan. Noin 30 %:lla COPD-potilaista nähtiin tilastollisesti merkitsevää laskua keuhkojen toiminnassa. Heikosti kehittyvät potilaat kärsivät myös muita useammin sairauden pahenemisvaiheista. Huonolle elämänlaadulle COPD:ssä ja elämän laadun kehitykselle astmassa ja COPD:ssä tunnistettiin useita kliinisiä riskitekijöitä. Työssä tarkasteltiin lisäksi väestöaineistossa näh

Published
2015

47. Innovation and paediatric medicine: stories from two European Networks

Author

TEDDY Task force in Europe for Drug Development for the Young, Network of Excellence, Paediatric, Aids, Paediatric Clinical Research Unit, Giaquinto, Carlo, and Member

Subjects
Nursing, business.industry, Health Policy, Medicine, business, Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Published
2010

48. Phenelzine produces subsensitivity to nicotine

Author

Department of Psychiatry and Mental Health Research University of Michigan, U.S.A., Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas, Houston Clinical Research Unit Harris County Psychiatric Center Houston, Texas, U.S.A., Dilsaver, Steven C., Hariharan, Meenatshisundanan, Davidson, Robin K., Department of Psychiatry and Mental Health Research University of Michigan, U.S.A., Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas, Houston Clinical Research Unit Harris County Psychiatric Center Houston, Texas, U.S.A., Dilsaver, Steven C., Hariharan, Meenatshisundanan, and Davidson, Robin K.

Abstract

Dilsaver, Steven C., Meenatshisundanan Hariharan, Robin K. Davidson: Phenelzine Produces Subsensitivity to Nicotine. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1993, 17(5): 847-860. 1. 1. The authors attempted to detect a possible effect of treatment with phenelzine on a physiological response to nicotine in the rat. 2. 2. Positive findings in an animal model suggest the feasibility of more complicated experiments in animals and the possibility of studies involving human subjects. 3. 3. Treatment of Sprague Dawley rats (n = 10) with phenelzine sulfate (15.0 mg/kg ip) every 48 hours for 14 days was associated with a 73.3% decrease in the hypothermic response to nicotine. 4. 4. Treatment with phenelzine did not enhance the rate of elimination of nicotine. 5. 5. The authors discuss a possible relationship between changes in nicotinic mechanisms and the therapeutic actions of drugs used to treat affective illness.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results